Literature DB >> 30778872

Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.

Muhammad B Hammami1, Ryan Gill2, Nikhil Thiruvengadam1, David Y Oh1, Kendall Beck1, Uma Mahadevan1, Michael G Kattah3.   

Abstract

Entities:  

Keywords:  Aeromonas; Aspirin; CTLA-4; Checkpoint inhibitor; Colitis; ICPI; Infliximab; PD-1; Vedolizumab

Mesh：

Substances：

Year:  2019        PMID： 30778872     DOI： 10.1007/s10620-019-05534-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  22 in total

Review 1.  Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective.

Authors:  Dipti M Karamchandani; Runjan Chetty
Journal:  J Clin Pathol       Date:  2018-04-27       Impact factor: 3.411

Review 2.  Coinhibitory Pathways in Immunotherapy for Cancer.

Authors:  Susanne H Baumeister; Gordon J Freeman; Glenn Dranoff; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2016-02-25       Impact factor: 28.527

Review 3.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

Authors:  C A Chambers; M S Kuhns; J G Egen; J P Allison
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 4.  Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Robert Sidlow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

5.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

6.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

7.  The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Trends Mol Med       Date:  2015-12-17       Impact factor: 11.951

8.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

Review 9.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 10.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Authors:  J M Michot; C Bigenwald; S Champiat; M Collins; F Carbonnel; S Postel-Vinay; A Berdelou; A Varga; R Bahleda; A Hollebecque; C Massard; A Fuerea; V Ribrag; A Gazzah; J P Armand; N Amellal; E Angevin; N Noel; C Boutros; C Mateus; C Robert; J C Soria; A Marabelle; O Lambotte
Journal:  Eur J Cancer       Date:  2016-01-05       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.